Płatkowska-Adamska, B.; Bociek, A.; Krupińska, J.; Kal, M.; Biskup, M.; Zarębska-Michaluk, D.; Odrobina, D.
BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy. Vaccines 2022, 10, 1878.
https://doi.org/10.3390/vaccines10111878
AMA Style
Płatkowska-Adamska B, Bociek A, Krupińska J, Kal M, Biskup M, Zarębska-Michaluk D, Odrobina D.
BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy. Vaccines. 2022; 10(11):1878.
https://doi.org/10.3390/vaccines10111878
Chicago/Turabian Style
Płatkowska-Adamska, Bernadetta, Agnieszka Bociek, Joanna Krupińska, Magdalena Kal, Michał Biskup, Dorota Zarębska-Michaluk, and Dominik Odrobina.
2022. "BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy" Vaccines 10, no. 11: 1878.
https://doi.org/10.3390/vaccines10111878
APA Style
Płatkowska-Adamska, B., Bociek, A., Krupińska, J., Kal, M., Biskup, M., Zarębska-Michaluk, D., & Odrobina, D.
(2022). BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy. Vaccines, 10(11), 1878.
https://doi.org/10.3390/vaccines10111878